The anti-cancer effect of the dual PI3K/mTOR inhibitor, NVP-BEZ235, on non-small cell lung cancer harboring wild-type EGFR
碩士 === 國立成功大學 === 臨床醫學研究所 === 101 === Despite of great advances in understanding the role of EGFR mutation in non-small cell lung cancer (NSCLC) and the corresponding target therapy, like gefitinib and erlotinib, we still have no effective and less toxic therapy for patients with NSCLC with wild-typ...
| Main Authors: | , |
|---|---|
| Other Authors: | |
| Format: | Others |
| Language: | zh-TW |
| Published: |
2013
|
| Online Access: | http://ndltd.ncl.edu.tw/handle/07541369744430624965 |